Dr Alex Rothman MA, BM BCh, MRes, PhD, MRCP
Wellcome Trust Clinical Research Career Development Fellow & NIHR Clinical Lecturer in Cardiology
Department of Infection, Immunity & Cardiovascular Disease
University of Sheffield
Beech Hill Road
Tel: +44 (0)114 215 9550
Fax: +44 (0)114 271 1863
I joined the University of Sheffield in 2008 as an Academic Clinical Fellow working as part of a team investigating the therapeutic tractability of inflammation in patients suffering heart attacks (the MRC ILA Heart study). Through my MRC Clinical Research Training Fellowship I developed an interest in the pathology and treatment of cardiovascular diseases and have been closely involved in studies investigating new therapies and devices for the treatment of pulmonary arterial hypertension, atherosclerosis and heart failure. I am currently a Wellcome Trust Career Development Fellow and NIHR Clinical Lecturer in cardiology and an Honorary Cardiology Registrar at Sheffield Teaching Hospitals NHS Trust.
My research interests are the pathology and treatment of cardiovascular and pulmonary vascular diseases. The MRC ILA Heart study was the first randomised study to demonstrate the therapeutic tractability of inflammatory signalling in coronary artery disease. Findings were published in the European Heart Journal and the New England Journal of Medicine, and validated by CANTOS, a phase III study of the interleukin-1 beta targeted therapy Canakinumab that demonstrated a reduction in recurrent cardiac events. My current work focuses on the pathology of pulmonary arterial hypertension and the development of novel therapeutic strategies. Recent pre-clinical studies have led to early phase clinical studies of pulmonary artery denervation and implantable pulmonary artery pressure monitors.
I enjoy lecturing clinical cardiology to both undergraduates and post-graduates and I teach clinical skills to medical students and doctors.
- Wellcome Trust Clinical Research Career Development Fellowship: Determining Novel SMURF1 Signalling Pathways and Precision Medicine Strategies in Patients with Pulmonary Arterial Hypertension, £460,409.
- MRC Confidence in Concepts, The Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients with Pulmonary Arterial Hypertension (FIT-PH), £65,610 (PI)
- British Heart Foundation, Development of a Prototype Pericardial Left Ventricular Assist Device, £249,967 (Co-I)
- Medtronic Inc. Non-invasive phenotyping of arrhythmias in pulmonary arterial hypertension, £200,000
- Association of Physicians of Great Britain and Ireland Young Investigator Award, £19,973
- Academy of Medical Sciences, Starter Grants for Clinical Lecturers: Inhibition of SMURF1 for the Treatment of Pulmonary Arterial Hypertension, £30,000
- EPSRC/HEFCE and Endotronix: Intra-arterial Pulmonary Artery Pressure Monitoring in Pulmonary Hypertension: Re-defining Clinical Measurement of Treatment Effect and Disease Progression, £84,711
- TROPHY: Therapeutic Intravascular Ultrasound for the treatment of pulmonary arterial hypertension (https://clinicaltrials.gov/ct2/show/NCT02516722)
- SIRONA: A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Heart Failure System in NYHA Class III Heart Failure Patients. (https://clinicaltrials.gov/ct2/show/NCT03375710)
For key publications see below. For a full list of publications click here.
- Rothman AM, Morton A & Crossman D (2018) Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine, 378, 196-200. View this article in WRRO
- Rothman AM & Crossman D (2017) The Canakinumab Antiinflammatory Thrombosis Outcome Study Trial—The Starting Gun Has Fired. Journal of Thoracic Disease, 9, 4922-4925. View this article in WRRO
- Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, Condliffe R, Charalampopoulos A, Rajaram S, Lawrie A , Campbell MJ et al (2017) Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 196(2). View this article in WRRO
- Billings CG, Hurdman JA, Condliffe RA, Elliot CA, Smith IA, Austin M, Armstrong IJ, Hamilton N, Charalampopoulos A, Sabroe I , Swift AJ et al (2017) Incremental Shuttle Walking Test Distance and Autonomic Dysfunction Predict Survival in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation. View this article in WRRO
- Zhang H-D, Lv Z-C, Wang L-T, Rothman A, Lian T-Y, He Y-Y, Wu Y, Lawrie A, Beghetti M & Jing Z-C (2017) Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. View this article in WRRO
- Hsiao ST, Spencer T, Boldock L, Prosseda SD, Xanthis I, Tovar-Lopez FJ, Van Beusekom HMM, Khamis RY, Foin N, Bowden N , Hussain A et al (2016) Endothelial repair in stented arteries is accelerated by inhibition of Rho-associated protein kinase. Cardiovascular Research, 112(3), 689-701. View this article in WRRO
- Rothman AM, Rowlands DJ & Lawrie A (2016) miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. Epigenomics. View this article in WRRO
- Rothman AM, Arnold N, Pickworth J, Iremonger J, Ciuclan L, Allan R, Guth-Gundel S, Southwood M, Morrell N, Thomas M , Francis S et al (2016) MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation, 126(7), 2495-2508. View this article in WRRO
- Zhou L, Zhang J, Jiang X-M, Xie D-J, Wang J-S, Li L, Li B, Wang Z-M, Rothman AMK, Lawrie A & Chen S-L (2015) Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. JACC Cardiovascular Interventions, 8(15), 2013-2023.
- Rothman AMK, Arnold ND, Chang W, Watson O, Swift AJ, Condliffe R, Elliot CA, Kiely DG, Suvarna SK, Gunn J & Lawrie A (2015) Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 8(11), e002569-e002569. View this article in WRRO
- Chen S-L, Zhang H, Xie D-J, Zhang J, Zhou L, Rothman AMK & Stone GW (2015) Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes. Circulation Cardiovascular Interventions, 8(11), e002837. View this article in WRRO
- Morton AC, Rothman AMK, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C & Banya W (2015) The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. European Heart Journal, 36(6), 377-384. View this article in WRRO
- Novodvorsky P, Watson O, Gray C, Wilkinson RN, Reeve S, Smythe C, Beniston R, Plant K, Maguire R, Rothman AMK , Elworthy S et al (2015) klf2ash317 Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes. PLoS ONE, 10(10), e0141611. View this article in WRRO
- Rothman AMK, Chico TJA & Lawrie A (2014) MicroRNA in pulmonary vascular disease.. Prog Mol Biol Transl Sci, 124, 43-63.
- Watson O, Novodvorsky P, Gray C, Rothman AMK, Lawrie A, Crossman DC, Haase A, McMahon K, Gering M, Van Eeden FJM & Chico TJA (2013) Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.. Cardiovasc Res, 100(2), 252-261. View this article in WRRO